Akari Therapeutics
Akari Therapeutics is a biopharmaceutical company focused on developing treatments for rare autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan (formerly Coversin), is a dual inhibitor of complement component 5 (C5) and leukotriene B4 (LTB4), currently in clinical trials for bullous pemphigoid, thrombotic microangiopathy, and other indications.
Top Stages
1 past transactions
Peak Bio
Acquisition in 2024
Peak Bio Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics addressing unmet needs in the areas of oncology, inflammation and rare diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.